

1 **Post-acute COVID-19 syndrome negatively impacts health and wellbeing despite less severe**
2 **acute infection**

3

4 Laura Tabacof¹, Jenna Tosto-Mancuso¹, Jamie Wood¹, Mar Cortes¹, Amy Kontorovich^{2,3}, Dayna
5 McCarthy¹, Dahlia Rizk⁴, Nicki Mohammadi⁵, Erica Breyman¹, Leila Nasr¹, Christopher
6 Kellner⁵, David Putrino^{1*}

7 ¹Abilities Research Center, Department of Rehabilitation and Human Performance, Icahn School
8 of Medicine at Mount Sinai, New York, NY

9 ²Zena and Michael A. Weiner Cardiovascular Institute, Icahn School of Medicine at Mount
10 Sinai, New York, NY

11 ³The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount
12 Sinai, New York, NY

13 ⁴Division of Hospital Medicine, Mount Sinai Beth Israel, New York, NY

14 ⁵Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY

15

16 * Corresponding author:

17 David Putrino

18 David.Putrino@mountsinai.org

19

20

21

22 **Abstract**

23 Introduction: One of the noted features of COVID-19 is the spectrum of expressivity in
24 symptoms among those with the disease, ranging from no or mild symptoms that may last a
25 small number of days, to severe and/or longer lasting symptoms. It is emerging that many
26 patients have long lasting symptoms, several months after initial infection with COVID-19. The
27 aim of this research was to characterize post-acute COVID-19 syndrome (PACS).

28 Methods: This was a retrospective cross-sectional observational study. Participants were patients
29 recovering from COVID-19 infection, enrolled in Mount Sinai Hospital's COVID-19 Precision
30 Recovery Program (PRP). Inclusion criteria were confirmed or probable (based on World Health
31 Organization criteria) initial diagnosis of COVID-19; post-acute COVID-19 syndrome (defined
32 as experiencing symptoms > 6 weeks since acute symptom onset) and being currently enrolled in
33 the PRP during the months of July and August 2020. Study survey data were collected using
34 REDCap. Demographic data, COVID-19 clinical data and patient-reported outcomes for
35 breathlessness (Medical Research Council Breathlessness Scale), fatigue and quality of life
36 (EuroQoL 5D-5L) were collected.

37 Results: 84 individuals with PACS were included. Symptoms persisted at mean (range) 151 (54
38 to 255) days. The most prevalent persistent symptoms were fatigue (92%), loss of
39 concentration/memory (74%), weakness (68%), headache (65%) and dizziness (64%). Most
40 participants reported increased levels of disability associated with breathlessness, increased
41 fatigue and reduced quality of life.

42 Conclusions: Persistent symptoms following COVID-19 infection are prevalent, debilitating and
43 appear to affect individuals regardless of acute infection severity or prior health status. More
44 detailed research is required in order to identify specific symptom clusters associated with
45 PACS, and to devise effective interventional strategies.

46 **Introduction**

47 One of the noted features of COVID-19 is the spectrum of expressivity in symptoms among
48 those with the disease, ranging from no or mild symptoms that may last a small number of days,
49 to severe and/or longer lasting symptoms [1, 2]. Severe acute COVID-19 symptoms can coincide
50 with respiratory failure and potentially death, or ongoing medical problems [3, 4]. The
51 symptomatology is complex [5, 6], and further work is required to describe the presence and
52 impact of longer lasting, or “post-acute” symptoms.

53 Symptom variability, especially in those with post-acute COVID-19 syndrome (PACS), presents
54 challenges to healthcare teams and patients. There are difficulties associated with devising and
55 delivering treatment programs amidst such disease novelty and diversity, which can be a source
56 of frustration for both clinicians and patients with COVID-19 alike. Moreover, the majority of
57 current healthcare efforts center on prevention and acute management [7, 8]. As a result, there
58 remains a limited understanding of, and resource allocation to, patients who continue to display
59 debilitating symptoms weeks and months following initial diagnosis. To date, the presence of
60 persistent symptoms months after initial COVID-19 diagnosis has only been described in brief,
61 and only in those whose acute illness was severe [9].

62 This study describes the detailed symptom data obtained from patients with PACS, and the
63 impact of these symptoms on self-reported physical function, quality of life and wellbeing. The
64 aim of this study was to characterise the persistent symptoms experienced by this cohort, and to
65 better inform healthcare provision for PACS.

66 **Materials and methods**

67 This was a cross-sectional observational study. Approval for the use of Precision Recovery
68 Program (PRP) data was provided by the Mount Sinai Program for Protection of Human Subjects
69 (IRB 20-03315).

70 **Participants**

71 Participants were patients with past COVID-19 infection, referred to Mount Sinai Hospital's
72 COVID-19 Precision Recovery Program (PRP) by a medical doctor, either during the acute or
73 post-acute phase of their disease. Inclusion criteria were confirmed or probable (i.e. confirmed
74 by a medical doctor in accordance with World Health Organization recommendations [WHO]
75 [10]) initial diagnosis of COVID-19; PACS (defined as experiencing symptoms > 6 weeks since
76 initial symptom onset); and provision of consent for clinical data to be used for research
77 purposes.

78 **Data collection and Outcomes**

79 Study data were collected and managed using REDCap (Research Electronic Data Capture)
80 electronic data capture tools hosted at Mount Sinai Health System. REDCap is a secure, web-
81 based application designed to support data capture for research studies [11]. Survey questions
82 used within REDCap were developed or selected by the Mount Sinai PRP team, including
83 components developed in conjunction with the WHO COVID-19 Technical Working Group.
84 Participants were provided with a link to the survey via email.

85 Baseline demographic data included gender, age, body mass index (BMI) and comorbidities.
86 COVID-19 clinical data included date of acute COVID-19 symptom onset, polymerase chain
87 reaction (PCR) and antibody test results, need for hospitalization and oxygen supplementation,
88 and acute and persistent symptoms. Patient-reported outcomes included screening tools for
89 breathlessness (Medical Research Council [MRC] Breathlessness Scale) [12], fatigue (visual
90 analogue scale) and quality of life (QoL) (EuroQol EQ-5D-5L) [13]. Participants were also asked
91 to rate whether their QoL was the same, better or worse following contracting COVID-19.

92 **Statistical analyses**

93 Statistical analyses were undertaken with Stata (StataCorp, Stata Statistical Software Release:
94 V.14). Data were analysed using descriptive statistics.

95 **Results**

96 Data is reported on the first 84 participants who met the inclusion criteria and responded to the
97 survey (Table 1). Eighty-two (98%) participants reported they underwent clinical testing for
98 COVID-19 via PCR and/or antibody tests, with 33 (39%) positive for the disease on at least one
99 test (Table1). The most prevalent symptoms experienced during acute COVID-19 infection were
100 dyspnoea (82%), fever/chills (79%), tinnitus (75%), loss of concentration/memory (73%) and
101 weakness (70%) (Figure 1).

102 Participants reported persistent symptoms at mean (range) 151 (54 to 255) days. Thirty-five
103 symptoms were reported among patients in the persistent phase, (all 19 acute symptoms plus 16
104 additional symptoms). The most prevalent persistent symptoms reported were fatigue (92%), loss
105 of concentration/memory (74%), weakness (68%), headache (65%) and dizziness (64%) (Figure
106 1). Patterns of persistent symptoms were similar in participants when divided into two groups,
107 being confirmed (via PCR and/or antibody tests) and probable COVID-19 infection (Figure 1).

108 The majority of participants (88%) reported increased levels of disability associated with
109 breathlessness on the MRC breathlessness scale (grades 2 and above). The mean (range) level of
110 fatigue reported was 56 (5 to 92) out of 100, with two thirds (65%) reporting fatigue levels of \geq
111 50/100. The domains of the EQ5D5L with the highest scores were 'usual activities' and
112 'pain/discomfort' (Table 1). Most participants (82%) reported that their QoL was worse now
113 compared to before contracting COVID-19.

114 **Discussion**

115 Post-acute COVID-19 syndrome is a collection of symptoms lingering long after acute infection.
116 Participants in this study reported a significant burden of symptomatology impacting their self-
117 reported physical function, quality of life and wellbeing.

118 The data presented in this study highlight the prevalence of persistent and debilitating symptoms
119 in a cohort of patients with previous confirmed or presumed COVID-19 infection that was
120 predominantly managed without the need for hospitalisation. This work builds upon the work of
121 Carfi et al (9) by demonstrating that serious sequelae are not limited to individuals who
122 experienced severe acute COVID-19 infection. Increased levels of fatigue, breathlessness and
123 weakness were common and likely affected the QoL scores observed on the EQ5D5L, in
124 particular relating to the ‘usual activities’ and ‘pain/discomfort’ domains.

125 The prevalence of these symptoms in previously healthy, relatively young adults, identifies long-
126 term sequelae that are associated with even less severe cases of COVID-19 infection. Although
127 the proportion of positive PCR and/or antibody tests was 39%, this reflects concerns raised
128 regarding the accuracy and potentially high rate of false-negatives seen in testing [14, 15, 16],
129 the limited access to testing earlier in the pandemic, and participants possibly delaying seeking
130 PCR tests during acute infection. The diagnosis of probable COVID-19 infection is supported by
131 the similarity in persistent symptom presentation shared with those who received positive
132 COVID-19 tests.

133 Long-lasting symptoms not yet defined by any current diagnostic paradigm can be extremely
134 daunting for patients and give rise to a sense of isolation. As such, clinicians are urged to
135 acknowledge the presence of the persistent symptoms that can impact the health and wellbeing of
136 patients with PACS.

137 Persistent symptoms following COVID-19 infection are prevalent, debilitating and appear to
138 affect patients regardless of acute infection severity or prior health status. It is more important

139 than ever to promote suppression and prevention strategies as more is understood about the
140 potential for COVID-19 infection to give way to long-term health effects in healthy individuals.
141 More detailed research is required in order to identify specific symptom clusters and predictors
142 associated with PACS, and to devise effective interventional strategies.

143

144 **Acknowledgements**

145 The authors would like to acknowledge the participants in the study, the frontline healthcare
146 workers at Mount Sinai Health System, and the wider research team at the Abilities Research
147 Center and the Center for Post-COVID Care at Mount Sinai.

148

149 **Supplementary material**

150 **Table 1. Participant (n=84) baseline demographic, COVID-19 clinical data and patient-**

151 **reported outcomes.** Data are presented as n (%) unless otherwise indicated.

152 aSerious medical complications reported included stroke, kidney and liver dysfunction.

153 MRC = Medical Research Council; VAS = visual analogue scale.

154

Demographic data	
Female	58 (69)
Age y, mean (range)	44 (12 to 81)
BMI kg/m ² , mean (range)	25 (16 to 44)
Most prevalent co-morbidities	
Asthma	22 (26)
Hypertension	9 (11)
Chronic immune deficiency	8 (10)
Obesity	5 (6)
Stroke/spinal cord injury	3 (4)

COVID-19 clinical data	
PCR completed	65 (77)
PCR positive of those completed	18 (28)
Antibody test completed	77 (92)
Antibody positive of those completed	30 (39)
Duration of symptoms in days, mean (range)	151 (54 to 255)
Hospitalized	8 (10)
Hospital duration in days, median (range)	1 (0 to 9)
Required oxygen supplementation	4 (5)

Serious medical complication ^a	6 (7)
---	-------

Patient-reported outcomes	
---------------------------	--

MRC breathlessness scale (1 to 5), mean (range)	2 (1 to 5)
Fatigue VAS (0 to 100), mean (range)	56 (5 to 92)
EQ-5D-5L domains (1 to 5), median (range)	
Mobility	2 (1 to 4)
Usual activities	3 (1 to 5)
Anxiety/depression	2 (1 to 5)
Self-care	1 (1 to 4)
Pain/discomfort	3 (1 to 5)
EQ-5D-5L health status VAS (0 to 100), mean (range)	53 (12 to 90)

155

156 **Figure 1. Symptoms reported by participants in the acute and persistent phases, including**
157 **additional persistent symptoms:** a) all participants (n=84); b) participants with confirmed
158 COVID-19 via PCR or antibody test (n=34); c) presumptive positive COVID-19 (n=50).

159

160 **References**

- 161 1. Pascarella G, Strumia A, Piliiego C, Bruno F, Del Buono R, Costa F, et al. COVID-19
162 diagnosis and management: a comprehensive review. *J Intern Med.* 2020
163 Aug;288(2):192–206.
- 164 2. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R,
165 Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features
166 of COVID-19: A systematic review and meta-analysis. *Travel Medicine and Infectious*
167 *Disease.* 2020 Mar;34:101623.
- 168 3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
169 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
170 study. *The Lancet.* 2020 Mar;395(10229):1054–62.
- 171 4. Chilimuri S, Sun H, Alemam A, Manthri N, Shehi E, Tejada J, et al. Predictors of
172 Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New
173 York City. *WestJEM [Internet].* 2020 Jul 8 [cited 2020 Sep 14];21(4). Available from:
174 <https://escholarship.org/uc/item/82x5x8g1>
- 175 5. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and
176 symptoms to determine if a patient presenting in primary care or hospital outpatient
177 settings has COVID-19 disease. Cochrane Infectious Diseases Group, editor. *Cochrane*
178 *Database of Systematic Reviews [Internet].* 2020 Jul 7 [cited 2020 Sep 14]; Available
179 from: <http://doi.wiley.com/10.1002/14651858.CD013665>
- 180 6. Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences:
181 Systematic review of the current evidence. *Brain, Behavior, and Immunity.* 2020
182 May;S0889159120309545.

- 183 7. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
184 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A
185 Review. *JAMA*. 2020 Aug 25;324(8):782.
- 186 8. Omer SB, Malani P, del Rio C. The COVID-19 Pandemic in the US: A Clinical Update.
187 *JAMA* [Internet]. 2020 Apr 6 [cited 2020 Sep 14]; Available from:
188 <https://jamanetwork.com/journals/jama/fullarticle/2764366>
- 189 9. Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study
190 Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 2020 Aug
191 11;324(6):603.
- 192 10. World Health Organization. WHO COVID-19 Case definition. Updated 7 August 2020.
193 WHO Reference number: WHO/2019-nCoV/Surveillance_Case_Definition/2020.1 Date
194 last accessed: 7 October 2020.
- 195 11. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
196 consortium: Building an international community of software platform partners. *Journal*
197 *of Biomedical Informatics*. 2019 Jul;95:103208.
- 198 12. Stenton C. The MRC breathlessness scale. *Occupational Medicine*. 2008 May
199 1;58(3):226–7.
- 200 13. Herdman M, Gudex C, Lloyd A, Janssen Mf, Kind P, Parkin D, et al. Development and
201 preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*.
202 2011 Dec;20(10):1727–36.
- 203 14. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative
204 Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by
205 Time Since Exposure. *Annals of Internal Medicine*. 2020 Aug 18;173(4):262–7.

- 206 15. Tabacof L, Kellner C, Breyman E, Dewil S, Braren S, Nasr L, et al. Remote Patient
207 Monitoring for Home Management of Coronavirus Disease 2019 in New York: A Cross-
208 Sectional Observational Study. *Telemedicine and e-Health*. 2020 Oct 13;tmj.2020.0339.
- 209 16. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection
210 — Challenges and Implications. *N Engl J Med*. 2020 Aug 6;383(6):e38.

Figure 1. Symptoms reported by participants in the acute and persistent phases, including additional persistent symptoms:
a) all participants (n=84); b) participants with confirmed COVID-19 via PCR or antibody test (n=34); c) presumptive positive COVID-19 (n=50).

